(؊)-(3S,4R,1R,6S)-4-(4-Benzyl-5-oxo-3,4-diazabicyclo[4.1.0]hept-2-en-2-yloxy)-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile and its derivatives with a modified benzyl group were synthesized with the objective of discovering novel ATP-sensitive potassium channel openers (PCOs) with a slow onset of action and a reduced tendency to induce tachycardia. Among the compounds synthesized, 4-(2-chlorobenzyl) derivative 5bB had potent hypotensive activity in spontaneously hypertensive rats (SHRs). In addition, compound 5bB showed the desired pharmacological profile with a slow onset and long duration of action and induction of only mild tachycardia. Compound 5bB was found to be quantitatively metabolized in rats to give active des-2-chlorobenzyl derivative 6B. These results suggest that the incorporation of an N-benzyl group is a useful method for the preparation of prodrugs, the function of which is to delay the onset and prolong the duration of action of the active substance.
The adenosine triphosphate (ATP) sensitive potassium channel is involved in the regulation of smooth muscle tone via an efflux of potassium ions from cells. Potassium channel openers (PCOs) such as levcromakalim (II), accelerate the efflux of potassium ions and then induce the dilation of smooth muscles of blood vessels. 1) Therefore, PCOs are expected to be useful agents for the treatment of cardiovascular diseases such as hypertension and angina pectoris. In fact, compound II showed potent antihypertensive activity in clinical trials. However, adverse reactions (ADRs) such as reflex tachycardia, headache and edema were frequently encountered.
2) These results led to preliminary conclusions that PCOs have no clinical advantage over conventional antihypertensive agents such as calcium channel blockers and angiotensin converting enzyme inhibitors.
It has been suggested that ADRs such as reflex tachycardia and headache might be compensatory reactions in response to the potent hypotensive effect induced immediately following the administration of PCOs, and we therefore expected that a slow onset of hypotensive action would probably decrease these ADRs. Based on this assumption, our investigation targeted PCOs showing a slow onset of action.
We have previously reported the synthesis and activity of a series of PCOs with a 4-[4-alkyl-3,4-diazabicyclo[4.1.0]heptenyloxy]-1-benzopyran pharmacophore (III). 3) In that study, we reported structure-activity relationships (SARs) focusing on variations of the 4-substituent of the 3,4-diazabicyclo[4.1.0]heptenyl group: straight-chain alkyl substituents gave compounds which showed potent hypotensive activity, but branched chain substituents such as an isobutyl group resulted in a loss of activity. We have systematically modified the 4-substituent of the 3,4-diazabicyclo[4.1.0]heptenyl group, and found that the incorporation of a 4-benzyl moiety such as compound IV produced PCOs with the desired pharmacological profiles. These compounds showed potent activity in vivo and, furthermore, they also had the desired profile i.e. a slow onset and long-duration of action.
In this paper, we describe the synthesis and biological activity of a series of 3,4-dihydro-2H-1-benzopyrans with 4-
Chemistry Chart 2 shows the general method for the synthesis of the 4-benzyl-3,4-diazabicyclo[4.1.0]heptenyl-1-benzopyran derivatives 5. Condensation of 1,2-cyclopropanedicarboxylic anhydride 4) (1) with benzylhydrazines 2a-j and phenethylhydrazine 2k gave (Ϯ)-3-benzyl-3,4-diazabicyclo[4.1.0]heptane-2,5-diones 3a-j and 3-phenethyl congener 3k, respectively, in 7-34% yields (Table 1) . Compounds 3a-k reacted with (3S,4S)-3,4-epoxy-2H-1-benzopyran-6-carbonitrile 5) (4) in the presence of pyridine in ethanol at reflux to afford a mixture of two diastereomers 5a-kA (less polar isomer, (3S,4R,1ЈS,6ЈR)) and 5a-kB (more polar isomer, (3S,4R,1ЈR,6ЈS)), which were separated by silica gel column chromatography (Table 2) .
Oxidative cleavage of the 4-methoxybenzyl group 6) of compounds 5iA and 5iB by 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in refluxing 1,2-dichloroethane afforded 4-unsubstituted diazabicyclo[4.1.0]heptenyl derivatives 6A and 6B, respectively, in good yield (Chart 3).
Alkylation of diazabicyclo[4.1.0]heptenyl derivative 6B with 4-cyanobenzyl bromide and 4-pyridylmethyl chloride in the presence of potassium carbonate produced 4-substituted diazabicyclo[4.1.0]heptenyl derivatives 5lB and 5mB, respectively, in good yield (Chart 3).
The 3D structures of compounds 5aB and 6B were determined by X-ray crystallography and are shown in Fig. 1 . Their configurations were determined to be (3S,4R,1ЈR,6ЈS) from correlation of the relative configurations of 5aB and 6B obtained by X-ray crystallographic analysis and the known absolute configuration (3S,4S) of intermediate 4.
5)
The NMR d values of the proton at the 4-position (H4) of the benzopyran nucleus of compounds 5 and 6 are listed in 3) Based on the observed relationships, all of the compounds 5b-mB were confirmed to have a (3S,4R,1ЈR,6ЈS)-configuration, the same as that of 5aB and 6B.
Results and Discussion
The in vivo antihypertensive activity (ED 50 mmHg ) of the compounds synthesized in this study was evaluated by oral administration to SHRs. The in vitro potassium channel opening activity of selected compounds was evaluated by their effects on K ϩ efflux (EC AUC0.2 ) in the rat isolated aorta using 86 Rb ϩ as a surrogate marker for K ϩ (Table 3 ).
7)
Most of the compounds tested exhibited potent antihypertensive activity in vivo. In particular, 4-benzyl, 4-(2-chlorobenzyl), 4-(4-chlorobenzyl), 4-(2-methylbenzyl), 4-(2,4-dichlorobenzyl), 4-(4-cyanobenzyl), 4-(4-pyridinylmethyl) and 4-phenethyl derivatives (5a,b,d,f,g,k,l,mB) showed high potency. The activities of the remaining compounds were comparable to that of levcromakalim (II) or less.
Although 4-benzyl and 4-(2-chlorobenzyl) derivatives 5a,bB had high potency in vivo, they showed no activity in the in vitro assay. Similarly, the 4-phenethyl derivative 5kB was inactive in vitro. Generation of an active metabolite seemed to be the most plausible explanation for this anomaly. It is known that an amide N-alkyl group, in particular an Nbenzyl group, is cleaved by cytochrome P-450. 8) Therefore, the common metabolite 6B may well be produced from compounds such as 5a-mB via cleavage of the 4-substituent on the diazabicyclo[4.1.0]heptenyl group. Therefore, we synthesized the suspected metabolite 6B to confirm our hypothesis. HPLC analysis of serum samples (Fig. 2) showed that compound 5bB was quantitatively converted into 6B after oral dosing. The administration of 0.5 mg/kg of 5bB to rats gave 6B with a t max of 12 h and C max of 0.377 mg/ml.
Since compounds 5a,c-mB are metabolized to the common active metabolite 6B, the in vivo SARs in this series of compounds may reflect relative susceptibility to metabolism of the 4-substituent of the 3,4-diazabicyclo[4.1.0]heptenyl group. Thus, 4-benzyl, 4-(2-chlorobenzyl), 4-(4-chlorobenzyl), 4-(2-methylbenzyl), 4-(2,4-dichlorobenzyl), 4-(4-cyanobenzyl), 4-(4-pyridinylmethyl) and 4-phenethyl groups are all probably easily removed by metabolism, since compounds 5a,b,d,f,g,k,l,mB, which have these substituents, show high potency in vivo. In contrast, 4-(3-chlorobenzyl), 4-(2,6-dichlorobenzyl), 4-(4-methybenzyl), 4-(4-sulfamoylbenzyl) and 4-(4-methoxybenzyl) groups seem to resist metabolism, as shown by the lower potency of compounds 5c,e,h,i,jB (Table 3) . Figure 3 shows the changes in systolic blood pressure (SBP) and heart rate (HR) after the oral administration of 4-(2-chlorobenzyl) derivative 5bB (0.1 mg/kg), 4-unsubstituted derivative 6B (0.03 mg/kg) and levcromakalim (II, 1 mg/kg) to SHRs. Compound 5bB exhibited a maximal decrease in blood pressure more than 8 h after administration, and the hypotensive effect lasted more than 24 h. Compound 6B also had long-lasting activity, but showed a maximal decrease in blood pressure at 1 h following administration. Compound II also had a rapid onset of action, and the hypotensive effect disappeared within 24 h. Moreover, compound II showed acute elevation of heart rate, while compound 5bB exhibited a gradual and less pronounced increase in heart rate. Thus, 5bB had a desired pharmacological profile with a slow onset, long duration of action, and less acute induced tachycardia.
The above results are consistent with the report that Y-27152 (Va, Chart 4) is a slow-onset and long-acting PCO with reduced tachycardia. 2, 9) This compound is also metabolized to an active metabolite, Y-26763 (Vb), through Odebenzylation in the liver. Taken together, these results indicate that a slow onset of action can partially overcome some of the adverse effects of first generation PCOs.
In conclusion, we prepared 4-(4-substituted-3,4-diazabicyclo[4.1.0]heptenyl)-2H-1-benzopyrans, and demonstrated that 4-(2-chlorobenzyl) derivative 5bB (DY-9804) is a slowonset and long-acting PCO which causes only mild tachycardia. Compound 5bB was metabolized to give active des-2- 6 mg/kg, p.o.) . The serum concentration of 6B was determined by HPLC. The data are meansϮS.E. for 3 rats. Compound 5bB was not detected at any sampling time following dosing. chlorobenzyl derivative 6B (DY-9708). These results suggest that N-benzyl substitution on amides or heterocycles may be a useful method for the preparation of prodrugs which display delayed onset and prolonged duration of action.
Further work is in progress to investigate the metabolism of N-debenzylation by cytochrome P450 in rats, and to determine the extent of metabolic activation in other mammals.
Experimental
Chemistry Melting points were determined on a Büchi 535 melting point apparatus and are uncorrected. Optical rotations were measured on a Horiba SEPA200 digital polarimeter. The 1 H-NMR spectra were recorded on a JEOL JNM-EX400 (400 MHz) spectrometer with tetramethylsilane (TMS) as an internal standard. Signal multiplicities are represented by s (singlet), d (doublet), dd (double doublet), t (triplet), q (quartet), m (multiplet), and br (broad). Chemical shifts are expressed in d values and the coupling constants in Hz. For column chromatography, silica gel (Kieselgel 60, 70-230 mesh, E. Merck) was used. Mass spectra (MS) were recorded on JEOL JMS-HX110 and JMS-AX505W instruments. Precoated Silica gel 60 F 254 plates with a layer thickness of 0.25 mm (E. Merck, Darmstadt, Germany) were used for thin-layer chromatography (TLC) to determine Rf values.
Starting Materials 1,2-Cyclopropanedicarboxylic anhydride (1) was prepared according to McCoy's method. 4) Benzylhydrazines (2a-k) were prepared from alkyl halide and hydrazine monohydrate according to the usual procedures.
10) Epoxide 4 was prepared according to the methods previously reported. 3-Benzyl-3,4-diazabicyclo[4.1.0]heptane-2,5-dione (3a) A solution of benzylhydrazine (2a, 45.8 g, 0.374 mol) in ethanol (50 ml) was added dropwise to a solution of 1 (42.0 g, 0.374 mol) in ethanol (150 ml) with stirring. The reaction mixture was heated under reflux for 15 h. After evaporation of the solvent in vacuo, the resulting residue was purified by silica gel column chromatography with ethyl acetate (EtOAc) as an eluent, followed by recrystallization from EtOAc to give 3a (24.1 g, 30%), mp 186-188°C. 1 Compounds 3b-k were prepared in an analogous manner (see Table 1 ) from 1 and the appropriate corresponding alkylhydrazines (2b-k). Compounds 5b-kA and 5b-kB were prepared in an analogous manner (see Table 2 Male spontaneously hypertensive rats were treated with compound 5bB (0.1 mg/kg, p.o., ), 6B (0.03 mg/kg, p.o., ᭹) and II (levcromakalim, 1 mg/kg, p.o., ᭡). The systolic blood pressure (SBP) and the heart rate (HR) were measured by a tail-cuff method, and the changes of SBP and HR are expressed vs. initial. The data are meansϮS.E. for 5 rats.
5) (؎)-

